H.C. Wainwright initiated coverage of PolyPid with a Buy rating and $16 price target. PolyPid is a clinical-stage pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies using its “transformational” Polymer-Lipid Encapsulation matriX technology, the analyst tells investors in a research note. The firm says the company’s pipeline candidates are designed to address unmet medical needs by pairing PLEX technology with approved agents.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYPD:
- PolyPid regains compliance with Nasdaq minimum closing bid price rule
- PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
- PolyPid announces publication of preclinical data on D-PLEX100
- PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
